Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, 100730, China.
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Interdiscip Sci. 2020 Jun;12(2):145-154. doi: 10.1007/s12539-020-00358-8. Epub 2020 Jan 25.
Although microsatellite instability (MSI) is most commonly detected in colorectal cancer (CRC), improvement in MSI analysis method can always help us better assessing MSI phenotypes and gaining useful information in challenging cases. The purpose of current study is to explore whether the ProDx® MSI analysis System (ProDx® MSI) can improve MSI classification in CRC.
We compared the MSI profiles of 97 FFPE samples from CRC patients by ProDx® MSI with Promega MSI analysis System 1.2 and NCI panel. The result is then confirmed by IHC test, which evaluate MMR protein expression. Furthermore, next generation sequencing was performed to double confirm the specimens with discordant results.
Among the total 97 CRC cases, 35 were scored as MSI-High by ProDx® MSI, Promega MSI analysis System 1.2, and NCI panel simultaneously. Three extra MSI-High cases were identified by ProDx® MSI. These three cases were classified as MSI-Low by NCI panel, while two of these as MSI-Low, and 1 as MSS by Promega MSI analysis System 1.2. ProDx® MSI had higher concordance with IHC detection compared with Promega MSI Analysis System 1.2 and NCI panel at 99.0%, 96.9%, and 95.9%, respectively. The ProDx® MSI distinguished MSI status with 100% sensitivity and 98.4% specificity. Our data showed that MSI-High phenotype occurred most frequently in tumor development stage I and stage II.
The colorectal cancer can be classified according to MSI status accurately by ProDx® MSI. More cases with MSI-High feature may be revealed by ProDx® MSI than by previous test systems in colorectal cancer.
微卫星不稳定性(MSI)在结直肠癌(CRC)中最常被检测到,但 MSI 分析方法的改进总能帮助我们更好地评估 MSI 表型,并在具有挑战性的病例中获得有用的信息。本研究旨在探讨 ProDx® MSI 分析系统(ProDx® MSI)是否能改善 CRC 中的 MSI 分类。
我们通过 ProDx® MSI 与 Promega MSI 分析系统 1.2 和 NCI 面板比较了 97 例来自 CRC 患者的 FFPE 样本的 MSI 图谱。结果通过免疫组化(IHC)试验进一步确认,评估 MMR 蛋白表达。此外,对结果不一致的标本进行下一代测序(NGS)以双重确认。
在 97 例 CRC 病例中,有 35 例同时被 ProDx® MSI、Promega MSI 分析系统 1.2 和 NCI 面板评为 MSI-High。ProDx® MSI 还额外鉴定了 3 例 MSI-High 病例。这 3 例病例被 NCI 面板归类为 MSI-Low,而 Promega MSI 分析系统 1.2 中有 2 例归类为 MSI-Low,1 例归类为 MSS。ProDx® MSI 与 IHC 检测的一致性高于 Promega MSI 分析系统 1.2 和 NCI 面板,分别为 99.0%、96.9%和 95.9%。ProDx® MSI 区分 MSI 状态的灵敏度为 100%,特异性为 98.4%。我们的数据显示,MSI-High 表型在肿瘤发展阶段 I 和 II 中最常发生。
ProDx® MSI 可准确地对结直肠癌进行 MSI 状态分类。ProDx® MSI 可能比以前的检测系统在结直肠癌中发现更多的 MSI-High 特征病例。